Business
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance
SILICON VALLEY, CA - May 14, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indicatio...
About this update from Abvc Biopharma, Inc.
[{"type":"image","caption":"","headline":"ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States","size":{"original":{"width":140,"height":78,"url":"https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X_qKvHxujBtXyrHhszohog--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNztjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/abacbb2aeeae890aef297a130fea97c7","width":140,"height":78}}},{"type":"text","content":"SILICON VALLEY, CA - May 14, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system (CNS), ophthalmology, and oncology/hematology indications, today announced that it has received official notice from the Nasdaq Listing Qualifications Department confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.","length":500,"tagName":"p"},{"type":"text","content":"According to Nasdaq's notification dated May 13, 2025, ABVC's common stock successfully maintained a closing bid price at or above $1.00 for 10 consecutive trading days from April 29, 2025 to May 12, 2025, satisfying the exchange's compliance standard for the referenced rule. This development formally closes this deficiency matter.","length":345,"tagName":"p"},{"type":"text","content":""This is more than a compliance milestone - it is a clear validation of our turnaround strategy and unwavering commitment to shareholder value," said Dr. Uttam Patil, ABVC Chief Executive Officer.","length":206,"tagName":"p"},{"type":"text","content":"Comparing fiscal year 2024 to 2023, ABVC has made significant strides:","length":70,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue increased by 234% year-over-year, driven by strategic out-licensing of its proprietary drug candidates.","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating expenses were reduced by 21%, demonstrating disciplined execution and operational efficiency.","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"EPS improved by 77%, reflecting the positive impact of stock-based compensation and streamline...